The North America Synthetic Biology Market is anticipated to witness robust growth from 2020 to 2035, driven by technological innovation, investment influx, and increasing adoption across multiple industries. The market size was valued at USD 10,400 Million in 2025 and is projected to reach USD 41,750 Million by 2035, expanding at a CAGR of 14.7% between 2024 and 2035.
The economic impact of tariffs on "North America Synthetic Biology Market".
Market Growth Drivers
Rising Investments and Funding: The surge in investments from both governmental bodies and private sector giants is significantly propelling growth within the synthetic biology sector in North America. For example, Ginkgo Bioworks has secured substantial funding rounds to expand its platform capabilities, enabling the development of new bio-based products ranging from pharmaceuticals to specialty chemicals. This influx of capital is fostering innovation and accelerating the development and commercialization of synthetic biological solutions by startups and established players alike.
Growing Demand Across Healthcare and Industrial Sectors: The rapid adoption of synthetic biology in drug discovery, vaccine development, and personalized medicine is a key driver for market growth. Companies such as Thermo Fisher Scientific are pioneering synthetic DNA and gene synthesis solutions to support advancements in precision medicine and diagnostics. Moreover, the industrial sector is utilizing engineered enzymes and organisms for sustainable production, reducing reliance on petrochemical feedstocks and lowering environmental impact.
Market Trends
Expansion of Genome Editing and CRISPR Technologies: The integration of advanced genome editing tools like CRISPR has transformed synthetic biology by enhancing precision and reducing development time. Companies like Editas Medicine are leveraging CRISPR to engineer cells for the treatment of genetic diseases, reflecting broader industry trends of using genome-editing techniques in therapeutic and agriculture applications.
Collaboration and Open Innovation: Strategic collaborations between companies, academic institutions, and research organizations are becoming increasingly prevalent. For instance, DNA Script partnered with Moderna in 2024 to accelerate on-demand mRNA synthesis platforms, showcasing a shift towards open innovation and ecosystem partnerships for faster technology breakthroughs and commercialization.
Market Opportunity
Expansion in Sustainable and Bio-based Manufacturing: There is a growing opportunity for synthetic biology firms to address sustainability challenges by enabling the production of bio-based plastics, fuels, and chemicals. For example, Zymergen is developing novel bio-manufactured materials for electronics and consumer goods, capitalizing on the demand for eco-friendly alternatives.
Precision Agriculture and Food Innovation: Emerging applications in agriculture, such as engineered crops and cellular agriculture, present lucrative possibilities. Companies like Calyxt are utilizing synthetic biology to develop more resilient and nutrient-rich crops, tapping into the growing need for food security and supply chain agility.
North America Synthetic Biology Market Revenue (USD Million), 2020-2035
The revenue chart illustrates steady market growth from 2020 to 2035. In 2020, the North America Synthetic Biology Market was valued at $3,100 million, experiencing consistent year-on-year increases driven by investment, technological advancements, and broadening application scopes. By 2025, the market is estimated to reach $10,400 million, continuing its upward trajectory to $41,750 million by 2035. Major growth inflections are observed post-2025, reflecting the mainstream uptake of synthetic biology technologies in biopharmaceuticals, agriculture, and industrial manufacturing. The chart highlights the market's evolution from an emerging sector into a pivotal driver for the region’s bioeconomy.
North America Synthetic Biology Market by Regional Share (%), 2025
The pie chart shows the regional distribution of the synthetic biology market in North America in 2025. The United States commands the largest share with 77%, reflecting its leadership in innovation, investment, and partnerships. Canada follows with 15%, which can be attributed to growing biotech clusters and supportive regulatory frameworks. Mexico captures 5%, with steady adoption in agri-bio industries. Other smaller regions collectively account for the remaining 3%. This regional distribution underscores the dominance of the US and highlights growth opportunities for other North American markets to expand synthetic biology adoption.
Recent Developments in the North America Synthetic Biology Market (Past 6 Months)
In February 2024, Ginkgo Bioworks unveiled a strategic collaboration with Bayer to engineer microbial solutions aimed at improving crop yields and sustainability in North American agriculture. This partnership is set to leverage synthetic biology for enhanced nitrogen fixation, with potential to minimize the need for chemical fertilizers.
In March 2024, DNA Script announced the commercial launch of its benchtop enzymatic DNA synthesis platform in the US and Canada. The system leverages proprietary synthetic biology techniques to accelerate synthetic gene assembly, empowering researchers with faster turnaround times and greater flexibility in sequencing projects.
In April 2024, Amyris Inc. secured a multi-year joint development agreement with DSM to produce sustainable bio-based materials for the personal care industry. This collaborative effort is anticipated to drive innovations in bio-manufacturing, providing scalable and eco-friendly alternatives to traditional chemical ingredients.
Press Releases